- Post-Effective Amendment to an S-8 filing (S-8 POS)
02 Julho 2010 - 5:39PM
Edgar (US Regulatory)
As filed with the Securities and Exchange Commission
on July 2, 2010
Registration Statement No. 333-129203
Registration Statement No. 333-149715
Registration Statement No. 333-
150184
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
POST-EFFECTIVE
AMENDMENT NO. 3 TO FORM S-8 REGISTRATION STATEMENT NO. 333-
129203
POST-EFFECTIVE
AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-
149715
POST-EFFECTIVE
AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-150184
FORM S-8
REGISTRATION
STATEMENT UNDER
THE
SECURITIES ACT OF 1933
JAVELIN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
88-0471759
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
125 CambridgePark Drive
Cambridge, MA 02140
(Address of Principal Executive Offices)
STOCK OPTION AGREEMENTS
2005 OMNIBUS STOCK INCENTIVE PLAN
2007 EMPLOYEE STOCK PURCHASE PLAN
(Full titles of the plans)
Brian J. Smith
Vice President and Secretary
Javelin Pharmaceuticals, Inc.
125 CambridgePark Drive
Cambridge, MA 02140
(617) 349-4500
(Name, address and telephone number,
including area code, of agent for service)
With copies to:
Craig A. Roeder
Michael F. DeFranco
Baker & McKenzie LLP
One Prudential Plaza
130 East Randolph Drive
Chicago, Illinois 60601
(312) 861-8000
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of large accelerated filer, accelerated
filer, and smaller reporting company in Rule 12b-2 of the Exchange
Act. (Check one):
Large accelerated filer
o
|
|
Accelerated
filer
x
|
Non-accelerated
filer
o
|
|
Smaller
reporting company
o
|
(Do
not check if a smaller reporting company)
|
|
|
DEREGISTRATION OF SECURITIES
This
Post-Effective Amendment, filed by Javelin Pharmaceuticals, Inc. (the Company),
deregisters all shares of common stock, par value $.001 per share, of the
Company (Common Stock) that had been registered for issuance under the
following Registration Statements on Form S-8 (together, the Registration
Statements) that remain unsold upon the termination of the offerings covered
by each of the Registration Statements:
·
File No. 333-129203,
pertaining to the registration of 8,685,299 shares of Common Stock issuable
under the Companys 2005 Omnibus Stock Incentive Plan, as amended (the 2005
Plan), which was filed with the Securities and Exchange Commission (the SEC)
on October 24, 2005 and was subsequently amended by post-effective
amendment no. 1 thereto filed with the SEC on October 5, 2006 and
post-effective amendment no. 2 thereto filed with the SEC on March 14,
2008;
·
File No. 333-149715, pertaining to the registration
of 1,500,000 shares of Common Stock, issuable under the 2005 Plan, which was
filed with the SEC on March 14, 2008; and
·
File No. 333-150184, pertaining to the registration
of 100,000 shares of Common Stock, issuable under the Companys 2007 Employee
Stock Purchase Plan, which was filed with the SEC on April 11, 2008.
On
April 17, 2010, the Company, Discus Acquisition Corporation (Purchaser),
a Delaware corporation and a wholly-owned subsidiary of Hospira, Inc., a
Delaware corporation (Parent), and Parent entered into an Agreement and Plan
of Merger (the Merger Agreement) which contemplated, among other things, that
Purchaser would merge with and into the Company, with the Company surviving as
a wholly-owned subsidiary of Parent (the Merger). On April 21, 2010,
pursuant to the terms of the Merger Agreement, Purchaser commenced a cash
tender offer, as amended from time to time (the Offer), to purchase all of
the outstanding shares of Common Stock at a price of $2.20 per share, net to
the seller in cash, without interest thereon and less any required withholding
taxes (the Per Share Amount).
The
Offer expired at midnight, New York City time, on June 30, 2010 (the end
of the day on June 30, 2010) and the Merger became effective on July 2,
2010 (the Effective Time) as a result of the filing of a Certificate of
Ownership and Merger with the Secretary of State of the State of Delaware. At
the Effective Time, each share of Common Stock that was issued and outstanding
immediately prior to the Effective Time (other than shares held by Parent, the
Company or their respective subsidiaries, or held by former stockholders of the
Company who properly asserted their appraisal rights under Delaware law) was
cancelled and automatically converted into the right to receive the Per Share
Amount.
As
a result of the Merger, the offerings pursuant to the Registration Statements
have been terminated. In accordance with undertakings made by the Company in
the Registration Statements to remove from registration, by means of
post-effective amendment, any of the securities remaining unsold at the
termination of such offerings, the Company hereby removes from registration the
securities of the Company registered but unsold under the Registration
Statements as of the Effective Time.
2
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, the registrant certifies
that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form S-8 and has duly caused this Post-Effective Amendment
to be signed on its behalf by the undersigned, thereunto duly authorized, in
the City of Lake Forest, State of Illinois, on July 2, 2010.
|
JAVELIN
PHARMACEUTICALS, INC.
|
|
|
|
|
|
By:
|
/s/
Brian J. Smith
|
|
|
Name: Brian
J. Smith
|
|
|
Title: Vice
President and Secretary
|
Pursuant
to the requirements of the Securities Act of 1933, this Post-Effective
Amendment has been signed by the following person in the capacities indicated
as of July 2, 2010.
Signature
|
|
Title
|
|
|
|
/s/
Richard J. Hoffman
|
|
President,
Treasurer and Director
|
Richard
J. Hoffman
|
|
(Principal
Executive Officer, Principal Financial Officer and Principal Accounting
Officer)
|
3
Javelin Pharmaceuticals (AMEX:JAV)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Javelin Pharmaceuticals (AMEX:JAV)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024